Business Context and Reporting Period
This Form 8-K was filed by Amphastar Pharmaceuticals, Inc. on June 26, 2014, with a report date of July 1, 2014. The filing documents corporate governance changes executed in connection with the closing of the Company's initial public offering (IPO).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and corporate structural amendments rather than financial performance data.
Material Changes
- Amended and Restated Certificate of Incorporation: Filed with the Delaware Secretary of State on June 26, 2014, effective upon the closing of the IPO.
- Amended and Restated Bylaws: Became effective on June 30, 2014, in connection with the IPO closing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the adoption of new corporate charter documents.
Key Facts for Investor Verification
- Verify the specific terms of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) to understand changes in corporate governance.
- Confirm the final closing date and share price of the IPO referenced in the filing.
- Review the Company's Form S-1 (File No. 333-196097) for detailed financial statements and risk factors not included in this 8-K.